hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06265233, orgStudyIdInfo id: 69668, briefTitle: ERP Plus Improv Group Therapy for OCD (IMPROVE Study), statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-09, primaryCompletionDateStruct date: 2025-01, completionDateStruct date: 2025-01, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: Stanford University, class: OTHER, descriptionModule briefSummary: The goal of this study is to pilot test a novel group therapy intervention for adults with OCD., conditionsModule conditions: Obsessive-Compulsive Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule interventions name: Group Improv sessions, interventions name: Group Exposure and Response Prevention (ERP) Therapy, outcomesModule primaryOutcomes measure: Change in the severity of OCD symptoms as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS), secondaryOutcomes measure: Change in Intolerance of Uncertainty Score, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: 401 Quarry, status: RECRUITING, city: Stanford, state: California, zip: 94304, country: United States, contacts name: Study Team, role: CONTACT, phone: 650-723-4095, email: ocdresearch@stanford.edu, geoPoint lat: 37.42411, lon: -122.16608, hasResults: False
protocolSection identificationModule nctId: NCT06265220, orgStudyIdInfo id: AB-101-03, briefTitle: AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-24, primaryCompletionDateStruct date: 2026-10, completionDateStruct date: 2026-10, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Artiva Biotherapeutics, Inc., class: INDUSTRY, descriptionModule briefSummary: AB-101 (also known as AlloNK) is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that is known to enhance the effect of monoclonal antibody therapies.This clinical trial will enroll adult patients with lupus nephritis Class III or IV either with or without the presence of Class V who relapsed or did not respond to previous standard of care treatment approaches.The primary objective is to assess the safety, tolerability and preliminary activity of AB-101 plus rituximab after cyclophosphamide and fludarabine in adult subjects with relapsed/refractory lupus nephritis Class III or IV, with or without the presence of Class V.Patients will be assigned to receive either AB-101 alone as monotherapy or in combination with rituximab. All patients will receive at least 1 treatment cycle of AB-101, followed by scheduled assessments of overall health and response status.Patients may receive up to 2 cycles of treatment spaced 24 weeks apart., conditionsModule conditions: Lupus Nephritis - WHO Class III, conditions: Lupus Nephritis - WHO Class IV, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 18, type: ESTIMATED, armsInterventionsModule interventions name: AB-101, interventions name: Cyclophosphamide, interventions name: Fludarabine, interventions name: Rituximab, outcomesModule primaryOutcomes measure: Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events, primaryOutcomes measure: AB-101 Clinical Activity, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of California, San Diego, status: RECRUITING, city: San Diego, state: California, zip: 92121, country: United States, contacts name: Bosco Trinh, role: CONTACT, contacts name: Bethany Karl, DO, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 32.71533, lon: -117.15726, hasResults: False
protocolSection identificationModule nctId: NCT06265207, orgStudyIdInfo id: ArdahanU-Simsekli-DS-02, briefTitle: The Effect of Virtual Reality on Pain, Anxiety and Satisfaction Level Before Mammography, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2025-03-15, completionDateStruct date: 2025-04-15, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Ardahan University, class: OTHER, collaborators name: Kafkas University, descriptionModule briefSummary: In this study, it is planned to determine the effect of virtual reality applied to women before mammography on pain, anxiety and satisfaction levels. For this purpose, individuals applying for breast cancer screening will first be randomly divided into experimental and control groups. Pain, anxiety and satisfaction level evaluation forms will be applied to the experimental group before the mammography procedure. A relaxing video will be watched with virtual reality glasses and the mammography will be performed. At the end of the mammography, the relevant forms will be applied to the individuals again. The control group will not be subjected to any additional application that will continue with the applied routine., conditionsModule conditions: Mammography, conditions: Early Diagnosis of Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Single Blind Parallel Group Randomized Controlled Trial, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: DOUBLE, maskingDescription: Since the researcher will be conducting the research, blinding will not be possible, and separate consent forms were prepared for the experimental and control groups, without specifying which group they were in, and it was planned to blind the participants in this way. In addition, in order to prevent statistical bias, it is planned to prevent bias in data analysis by coding the data as first group and second group, rather than experimental and control group, when entering the data into SPSS, and by not giving information about which group is the experiment and which is the control group., whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 78, type: ESTIMATED, armsInterventionsModule interventions name: Virtual reality, interventions name: routine maintenance, outcomesModule primaryOutcomes measure: Visual Comparison Scale, primaryOutcomes measure: State Anxiety Inventory, primaryOutcomes measure: Satisfaction Evaluation Scale, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 69 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06265194, orgStudyIdInfo id: ZAT2024, briefTitle: Effect of EMDR in the Treatment of Fibromyalgia, acronym: EMDR, statusModule overallStatus: COMPLETED, startDateStruct date: 2015-01-01, primaryCompletionDateStruct date: 2018-01-01, completionDateStruct date: 2018-03, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Academy of Therapeutic Sciences, Turkey, class: OTHER, descriptionModule briefSummary: The goal of this randomized-controlled study is to investigate the impact of EMDR therapy on fibromyalgia symptoms, depression, sleep quality, and traumatic stress in fibromyalgia patients.The main questions it aims to answer are:* Does EMDR become useful in relieving pain and complaints in fibromyalgia patients?* Is specific EMDR Fibromyalgia Protocol effective of fibromyalgia patients?* Does EMDR therapy decrease depression, sleep quality and traumatic stress symptoms of individuals with fibromyalgia?, conditionsModule conditions: Fibromyalgia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Eligible participants were randomized into two groups: one receiving TAU treatment (control group) and the other receiving both TAU and EMDR (experimental group)., primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: Participants do not have the knowledge of group interventions., whoMasked: PARTICIPANT, enrollmentInfo count: 79, type: ACTUAL, armsInterventionsModule interventions name: EMDR, interventions name: TAU, outcomesModule primaryOutcomes measure: Fibromyalgia Impact Questionnaire (FIQ), primaryOutcomes measure: Pittsburgh Sleep Quality Index (PSQI), primaryOutcomes measure: Trauma Symptom Checklist-40 (TSC-40), secondaryOutcomes measure: Beck Depression Inventory (BDI), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06265181, orgStudyIdInfo id: AIBU-SBF-SK-04, briefTitle: The Effect of Diabetes Coaching on Distress and Diabetes Self-Management, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-27, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2027-12-31, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Abant Izzet Baysal University, class: OTHER, descriptionModule briefSummary: This research is a randomized controlled, experimental study planned to evaluate the effect of diabetes coaching on diabetes self-management, glycosylated hemoglobin and diabetes distress levels in individuals with type 2 diabetes.The research is planned to start on 01.01.2024. Participants will be divided into experimental and control groups using the block randomization method. Participants in the experimental group will first receive 8 sessions of diabetes coaching every 10 days after the chemistry interview. No intervention will be made to the control group. The preliminary implementation of the research will be carried out with 4 individuals with diabetes who voluntarily accept participation and meet the inclusion criteria. Data will be collected by face-to-face interview method. Data will be analyzed with IBM SPSS V23 program., conditionsModule conditions: Diabetes Mellitus, Type 2, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Experimental and control group., primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, maskingDescription: When the researcher evaluates the participant according to the inclusion criteria, written consent will be obtained from the participant and pre-evaluation forms will be applied when compliance with the criteria is achieved. Afterwards, the participant's group will be notified to the researcher by the independent researcher and randomization will be carried out. With this; Data entries will be made by an independent researcher as group A and group B, without writing the group names. Until the data analysis and reporting is completed, the statistician will be blinded to which group is the intervention and which group is the control., whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 64, type: ESTIMATED, armsInterventionsModule interventions name: Diabetes coaching, outcomesModule primaryOutcomes measure: Type 2 Diabetes Self-Management Scale, secondaryOutcomes measure: Diabetes Distress Scale, secondaryOutcomes measure: HbA1c Monitoring Form, secondaryOutcomes measure: Introductory Features Form, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06265168, orgStudyIdInfo id: req-2023-01512; am23Sutter3, briefTitle: Comprehensive Observations and Multidisciplinary Approaches in the Management of Unconscious Patients, acronym: COMA, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: University Hospital, Basel, Switzerland, class: OTHER, descriptionModule briefSummary: This prospective observational high-fidelity simulation study aims to observe and better understand how physicians from different disciplines differentiate in the management of a comatose patient and how their diagnostic and treatment approaches adhere to current recommendations in a highly standardized simulated scenario. The results gained by this study will give more insight into the current quality of diagnostic procedures and treatment and help refine recommendations in this context. The investigators hypothesize that physicians do not strictly adhere (regarding diagnostic approach and treatment) to current guidelines/recommendations when confronted with a comatose patient., conditionsModule conditions: Coma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Simulation, outcomesModule primaryOutcomes measure: To reveal diagnostic and treatment approaches of physicians from different disciplines when confronted with a comatose patient., secondaryOutcomes measure: Physicians' grade of adherence to current recommendations regarding diagnostic procedures and treatment of a comatose patient, secondaryOutcomes measure: Participants' self-evaluation of their performance in hindsight, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University Hospital Basel, status: RECRUITING, city: Basel, country: Switzerland, contacts name: Prof. Dr. Sutter, role: CONTACT, contacts name: Liliane Nueesch, role: CONTACT, geoPoint lat: 47.55839, lon: 7.57327, hasResults: False
protocolSection identificationModule nctId: NCT06265155, orgStudyIdInfo id: SuzhouMHAnhui, briefTitle: Triggers of Acute Ischemic Stroke Due to Large Vessel Occlusion, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-01, primaryCompletionDateStruct date: 2025-06-30, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Anzhi Li, class: OTHER, descriptionModule briefSummary: Acute ischemic stroke has a high incidence, ischemic stroke caused by large vessel occlusion is serious and has a poor prognosis, and its triggers in the short term before onset are not clear. The aim of this study was to evaluate the short-term risk of acute ischemic stroke caused by multiple triggers. In this trial, through a case-crossover study design, patients were asked about the exposure to each trigger in the previous year and the exposure during the preictal risk period (the exposure observed during the risk period) for each potential trigger of acute ischemic stroke caused by large vessel occlusion. To evaluate the relative risk of ischemic stroke resulting from exposure to triggers, comparing exposure during the dangerous period with the usual frequency of exposure. Relative risks and corresponding 95% CIs were estimated for past-year exposure and past-year mean exposure (assessed as chronic risk factors) and time to last exposure (assessed as triggers). Scientifically evaluate exposure to a range of potential triggers, including infection, mood, smoking, alcohol consumption, diarrhea and vomiting, extreme temperature changes, and several factors that increase blood pressure and their risk of developing acute ischemic stroke., conditionsModule conditions: Triggers of Acute Ischemic Stroke Due to Large Vessel Occlusion, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CROSSOVER, timePerspective: PROSPECTIVE, enrollmentInfo count: 302, type: ESTIMATED, outcomesModule primaryOutcomes measure: RR values for exposure during the risk period versus exposure in the past year for each trigger, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Suzhou Hospital Anhui Medical University, status: RECRUITING, city: Suzhou, state: Anhui, zip: 234000, country: China, contacts name: Anzhi Li, B.S., role: CONTACT, phone: +8615903860581, email: 365819805@qq.com, contacts name: Zhengfei Ma, M.D., role: CONTACT, phone: 13866586362, email: Zhengfeima@126.com, geoPoint lat: 31.30408, lon: 120.59538, hasResults: False
protocolSection identificationModule nctId: NCT06265129, orgStudyIdInfo id: R.23.12.2429, briefTitle: The Association Between Obstructive Sleep Apnea Severity and Red Blood Cells Indices, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-03-20, primaryCompletionDateStruct date: 2023-10-20, completionDateStruct date: 2023-12-20, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Mansoura University, class: OTHER, descriptionModule briefSummary: Obstructive sleep apnea syndrome (OSAS) is characterized by recurrent episodes of obstructive events (apnea and hypopnea) and intermittent hypoxia, which in turn contributes to the systemic inflammation that underlies this disease and its consequences (Ryan et al 2009, Gileles-Hillel et al 2014). This systemic inflammation leads to endothelial dysfunction, which contributes to the pathogenesis of cardiovascular complications in OSAS, in addition to the exposure to risk factors, such as male gender, older age, obesity, and lack of exercise (Lorenzi Filho et al 2010). Some red blood cells (RBC) and platelets indices have emerged as inflammatory biomarkers in various diseases (Tertemiz et al 2016) The severity of OSA is significantly associated with increase hematocrit, even after controlling for possible confounding variables. However, nocturnal hypoxemia in OSA does not usually lead to clinical polycythemia (Choi et al 2006). In patients referred with a clinical diagnosis of OSAS, RDW may be a marker for the severity of the condition. As RDW is usually included in a complete blood count, it could provide an inexpensive tool for triaging OSAS patients for polysomnography evaluation (Sökücü et al 2012). The hematological indices white blood cell count (WBC), neutrophil count, lymphocyte count, mean platelet volume (MPV), platelet distribution width (PDW), and red blood cell distribution width (RDW) have been proposed as alternative markers to those normally used clinically, e.g., interleukin-6 (IL6) and C-reactive protein, to evaluate the burden of inflammation in OSAS (Wu et al 2018), conditionsModule conditions: Obstructive Sleep Apnea, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 30, type: ACTUAL, armsInterventionsModule interventions name: Complete blood picture (done in the morning after the night of monitored sleep by PSG. With stress on red blood cell indices (RBC count, MCV, MCH, RDW), outcomesModule primaryOutcomes measure: Red Blood Cells Indices, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tamer Awad Elsayed, city: Mansoura, state: Dakhlia, zip: 050, country: Egypt, geoPoint lat: 31.03637, lon: 31.38069, hasResults: False
protocolSection identificationModule nctId: NCT06265116, orgStudyIdInfo id: A0801024 CD, briefTitle: One-Step Universal Adhesives: A 3-year Clinical Trial in Class II Composite Restorations, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-23, primaryCompletionDateStruct date: 2027-01-23, completionDateStruct date: 2027-01-30, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Mansoura University, class: OTHER, descriptionModule briefSummary: to evaluate and compare the clinical performance and periodontal responses of four commercially available one-step universal adhesives with different formulations in Class II composite restorations over a three-year period., conditionsModule conditions: Dental Caries Class II, conditions: Marginal Integrity of Composite Restorations With Universal Adhesives, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 48, type: ESTIMATED, armsInterventionsModule interventions name: One-step universal adhesive, outcomesModule primaryOutcomes measure: Percentage of functional and biological properties for each group, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 40 Years, stdAges: ADULT, contactsLocationsModule locations facility: Omar Abd El-Fattah Abd El-Maksoud, status: RECRUITING, city: Mansoura, state: Dakahlia, zip: 35516, country: Egypt, contacts name: Omar A Abd El-Maksoud, role: CONTACT, phone: 01024366555, email: omarabdelfata7.92@gmail.com, geoPoint lat: 31.03637, lon: 31.38069, hasResults: False
protocolSection identificationModule nctId: NCT06265077, orgStudyIdInfo id: 2023-199, briefTitle: Novel Preventive Approach Against Filgrastim-Induced Bone Pain in Cancer Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02, primaryCompletionDateStruct date: 2024-08, completionDateStruct date: 2024-08, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Noha Mansour, class: OTHER, descriptionModule briefSummary: No randomized controlled trial evaluated the safety and efficacy of double blockade on G-CSF induced bone pain. Therefore, this study aims to evaluate the efficacy and safety of double blockade on the incidence and severity of G-CSF induced bone pain., conditionsModule conditions: Breast Cancer, conditions: Filgrastim Adverse Reaction, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Placebo, interventions name: famotidine and loratadine, outcomesModule primaryOutcomes measure: The incidence of grade 2 or 3 bone pain in cycle 1 according to Common Terminology Criteria for Adverse Events, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False